Browsing Tag
abiraterone acetate
2 posts
AKEEGA moves upstream as CHMP backs PARP inhibition in metastatic hormone-sensitive prostate cancer
Find out how CHMP support for AKEEGA could shift PARP inhibitors into earlier prostate cancer treatment and reshape precision oncology strategy.
February 9, 2026
Johnson & Johnson expands AKEEGA’s reach with FDA nod in BRCA2-mutated metastatic castration-sensitive prostate cancer
Johnson & Johnson’s AKEEGA secures FDA approval for BRCA2-mutated prostate cancer, reshaping early-stage treatment and signaling a shift toward genomic-first therapy.
December 14, 2025